Cargando…
Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure
OBJECTIVES: Our aim was to compare an AntiCD20 therapy (rituximab) for rheumatoid arthritis in two patient populations (Group 1), anti-TNFα naïve patients and inadequate responders to Anti-TNFα therapy (Group 2). METHODS: We analyzed the efficacy of the drug Rituximab (RTX) in RA patients who failed...
Autores principales: | Gutierrez-Gonzalez, Luis Arturo, Gudiño, Marco Antonio Rivera, Ceija, Ibell Oropeza, Leonet, Marialina Marin, Noguera, Zair Tovar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812784/ https://www.ncbi.nlm.nih.gov/pubmed/24179556 http://dx.doi.org/10.2174/1874312920130913004 |
Ejemplares similares
-
Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015) -
Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab
por: Łosińska, Katarzyna, et al.
Publicado: (2023) -
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015) -
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012) -
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)